Jane Street Group LLC Buys 70,330 Shares of Prestige Consumer Healthcare Inc. $PBH

Key Points

• Jane Street Group LLC significantly increased its stake in Prestige Consumer Healthcare by 204% during the 1st quarter, now holding approximately $9 million worth of shares.
• Prestige Consumer Healthcare recently reported a loss in earnings per share of $0.95, missing estimates and reflecting a 6.6% decline in revenue compared to the previous year.
• Multiple analysts have downgraded Prestige Consumer Healthcare's rating, with Wall Street Zen moving it from "buy" to "hold," while Canaccord Genuity reduced the price target from $105 to $100.

Jane Street Group LLC lifted its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 204.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 104,802 shares of the company's stock after purchasing an additional 70,330 shares during the quarter. Jane Street Group LLC owned 0.21% of Prestige Consumer Healthcare worth $9,010,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in PBH. Tower Research Capital LLC TRC lifted its position in Prestige Consumer Healthcare by 97.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,925 shares of the company's stock worth $150,000 after buying an additional 950 shares in the last quarter. Susquehanna International Group LLP raised its holdings in Prestige Consumer Healthcare by 118.1% during the fourth quarter. Susquehanna International Group LLP now owns 21,189 shares of the company's stock worth $1,655,000 after acquiring an additional 11,475 shares in the last quarter. Tudor Investment Corp ET AL bought a new stake in Prestige Consumer Healthcare during the fourth quarter worth about $1,315,000. Northern Trust Corp raised its holdings in Prestige Consumer Healthcare by 10.9% during the fourth quarter. Northern Trust Corp now owns 813,076 shares of the company's stock worth $63,493,000 after acquiring an additional 80,055 shares in the last quarter. Finally, Lido Advisors LLC bought a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth approximately $226,000. Institutional investors own 99.95% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Canaccord Genuity Group dropped their target price on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Wall Street Zen cut Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Finally, Royal Bank Of Canada upgraded Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Three research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, Prestige Consumer Healthcare has an average rating of "Moderate Buy" and a consensus price target of $93.33.

Prestige Consumer Healthcare Trading Down 0.3%

PBH traded down $0.23 during trading on Thursday, reaching $66.68. 510,911 shares of the stock traded hands, compared to its average volume of 403,355. The stock has a market capitalization of $3.28 billion, a PE ratio of 15.65, a P/E/G ratio of 2.15 and a beta of 0.46. Prestige Consumer Healthcare Inc. has a 12 month low of $62.95 and a 12 month high of $90.04. The stock's 50-day moving average is $72.64 and its 200 day moving average is $80.20. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The company had revenue of $249.53 million for the quarter, compared to the consensus estimate of $260.71 million. During the same period last year, the company earned $0.90 EPS. Prestige Consumer Healthcare's revenue for the quarter was down 6.6% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.